IPO Journey
bioAffinity Technologies, Inc.
IPO Date: June 18, 2026 · 13 filings tracked
Final Offer Terms
Ticker
BIAF
Exchange
The Nasdaq Capital Market
Offer Price
$0.80
Shares Offered
1,040,000
Estimated Proceeds
$832.0K
Underwriters
Led by WallachBeth Capital LLC
Filing Timeline
1
S-1
April 11, 2025
- CyPath® Lung test offers a non-invasive, automated solution for early lung cancer detection.
- Significant revenue growth, climbing from $2.5 million in 2023 to $9.4 million in 2024.
2
S-1
May 2, 2025
- Innovative non-invasive early lung cancer detection using CyPath® Lung technology
- Significant revenue growth, increasing from $2.5 million in 2023 to $9.4 million in 2024
3
S-1/A
May 5, 2025
- Innovative non-invasive lung cancer diagnostic test (CyPath® Lung)
- Significant revenue growth from $2.5M in 2023 to $9.4M in 2024
4
424B4
Material Update
May 7, 2025
- Innovative non-invasive lung cancer diagnostic test (CyPath® Lung)
- Significant revenue growth from $2.5M in 2023 to $9.4M in 2024
Changes from previous filing
- ▸ Ticker symbol: BIAF
- ▸ Exchange: Nasdaq Capital Market
- ▸ Final offer price: $0.32 per share
- ▸ Shares offered: 7,784,904
- ▸ Estimated proceeds: $2M
- ▸ Underwriters: WallachBeth Capital, LLC
5
S-1
August 29, 2025
- Innovative early-detection technology for lung cancer using CyPath® Lung
- Proprietary AI-driven diagnostic analysis of cellular samples
Changes from previous filing
- ▸ Shares offered: 12,611,253
- ▸ Underwriters: WallachBeth Capital LLC
6
S-1/A
September 15, 2025
- Innovative CyPath® Lung test offers a non-invasive alternative to traditional lung biopsies
- Proprietary technology uses chemical markers to make cancer cells glow for easier detection
Changes from previous filing
- ▸ Shares offered: 32,495,628
7
S-1
September 24, 2025
- Focuses on early-stage lung cancer detection via the proprietary CyPath® Lung test.
- Utilizes innovative fluorescent dye technology to identify cancer cells in mucus samples.
Changes from previous filing
- ▸ Final offer price: $5.48 per share
- ▸ Shares offered: 729,927
- ▸ Estimated proceeds: $3M
- ▸ Underwriters: WallachBeth Capital LLC
8
S-1/A
September 25, 2025
- Developed CyPath® Lung, a non-invasive diagnostic test for early-stage lung cancer
- Utilizes innovative flow cytometry technology to identify cancer cells in phlegm
9
424B4
Material Update
September 30, 2025
- Innovative non-invasive early-stage lung cancer detection via CyPath® Lung
- Proprietary diagnostic technology using fluorescent cell-labeling
Changes from previous filing
- ▸ Final offer price: $2.5 per share
- ▸ Shares offered: 1,047,694
- ▸ Estimated proceeds: $2M
10
S-1
April 30, 2026
- Flagship CyPath® Lung test uses AI for early-stage (Stage 1A) lung cancer detection.
- Transitioned to in-house operations via Precision Pathology Laboratory Services to capture full revenue.
Changes from previous filing
- ▸ Exchange: The Nasdaq Capital Market
- ▸ Shares offered: 497,483
11
S-1
June 12, 2026
- Pioneering non-invasive lung cancer detection via the CyPath® Lung test.
- Scalable automated technology that identifies cancer cells in phlegm.
Changes from previous filing
- ▸ Final offer price: $1.52 per share
- ▸ Shares offered: 2,631,579
- ▸ Estimated proceeds: $4M
- ▸ Underwriters: WallachBeth Capital LLC
12
S-1/A
June 16, 2026
- Focuses on early-stage lung cancer detection using non-invasive sputum analysis.
- Proprietary CyPath® Lung technology utilizes flow cytometry to identify cancer cells.
Changes from previous filing
- ▸ Ticker symbol removed
424B4
Final Pricing
June 18, 2026
- Proprietary AI-driven diagnostics for non-invasive lung cancer detection
- High clinical performance with 92% sensitivity and 87% specificity
Changes from previous filing
- ▸ Ticker symbol: BIAF
- ▸ Exchange: The Nasdaq Capital Market
- ▸ Final offer price: $0.8 per share
- ▸ Shares offered: 1,040,000
- ▸ Estimated proceeds: $0M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.